Comparative pharmacoeconomic analysis schemes dosage of hormonal stimulation during in vitro fertilization
Abstract
Purpose: Definition the scheme of hormonal stimulation, which is the most pharmacoeconomical founded. Methods: Pharmacoeconomic analysis was performed using the cost minimization analysis on the assumption of equal effectiveness compared schemes of hormonal stimulation, which was confirmed in the review of clinical trials and meta-analysis. To estimate the cost of drugs for ovulation induction we used registered VED rates and recommended in the instructions for medical use and the standard of care for infertility using assisted reproductive technologies dosing regimens. Results: The cost of the courses of drugs (1) corifollitropin a + ganirelix (32.9%), corifolhtropin a + ganirelix + follitropin (3 (67.1%) and (2) follitropin a + cetrorelix was 38 108.5 rub. and 47 102 rub., respectively. Cost saving of the budget by using the first scheme was 8 993.5 rub. for one course of in vitro fertilization. Conclusions: The scheme of hormonal stimulation using corifollitropin a is more pharmacoeconomical reasonable.
About the Authors
I. S. Krysanov
Postgraduate Medical Institute, Moscow National University of Food Production
Russian Federation
Russian Federation
V. S. Krysanova
Medical University First Moscow State Medical University named after I.M. Sechenov Ministry of Health
Russian Federation
Russian Federation
A. G. Tolkushin
LLC «MSD Pharmaceuticals»
Russian Federation
Russian Federation
References
1. Devroey Р, Boostanfar R., Koper N.P., Mannaerts В.М., ljzerman-Boon PC., Fauser В.С. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. // Hum Reprod 2009 Dec;24(12):3063-72.
2. Obruca A. et al. The corifollitropin alfa ENSURE study group Corifollitropin a for ovarian stimulation in IVF: a randomized trial in lower body-weight women. // Reproductive BioMedicine Online (2010).
3. Pouwer A. W., Farquhar C, Jan AM. Kremer. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. // Intervention Review. Published Online: 13 JUN 2012.
4. Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень ЖНВЛП на 06.07.2015г. (http://grls.rosminzdrav.ru/PriceLims.aspx).
5. Стандарт медицинской помощи при бесплодии с использованием вспомогательных репродуктивных технологий. Утвержден Приказом Минздрава РФ от 30 октября 2012 № 556н.
6. Официальная инструкция по применению лекарственного препарата Оргалутран*. Государственный реестр лекарственных средств. Официальный сайт, [электронный ресурс: http://grls.rosminzdrav.ru/]. Дата обращения 6 июля 2015 года.
7. Официальная инструкция по применению лекарственного препарата Цетротид*. Государственный реестр лекарственных средств. Официальный сайт, [электронный ресурс: http://grls.rosminzdrav.ru/]. Дата обращения 6 июля 2015 года.
8. Постановление Правительства РФ от 28.11.2014 г. №1273 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2015 год и на плановый период 2016 и 2017 годов».
9. Williams R.S., Theresa Vensel, Christopher L. Sistrom, Simon Kipersztok, Pregnancy rates in varying age groups after in vitro fertilization: A comparison of follitropin alfa (Gonal F) and follitropin beta (Follistim). // Am J Obstet Gynecol 189:342-7,2003.
10. Harlin /., Aanesen A, Csemiczky G., Wramsby H„ Fried G. Delivery rates following I VF treatment, using two recombinant FSH preparations for ovarian stimulation. // Human Reproduction Vol.17, No.2 pp. 304-309, 2002.
Review
For citations:
Krysanov I.S., Krysanova V.S., Tolkushin A.G. Comparative pharmacoeconomic analysis schemes dosage of hormonal stimulation during in vitro fertilization. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2015;(3):30-33. (In Russ.)
Views:
1096
Email this article 